NASDAQ:CARA
Delisted

Cara Therapeutics Stock News

etoro logo Buy CARA
*Your capital is at risk
$5.32
+0 (+0%)
At Close: Jul 14, 2025
– U.S. Food and Drug Administration (FDA) Accepts New Drug Application (NDA) Filing and Grants Priority Review for KORSUVA™ Injection in CKD-aP –
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Cara Therapeutics Stock Is Crashing Today

11:33am, Thursday, 29'th Apr 2021
The company reported disappointing results from a phase 2 study.
The stock price of Cara Therapeutics Inc (NASDAQ: CARA) fell from $25.79 to $15.64 as of 8:38 AM ET. This is why it happened.
Cara Therapeutics: Upcoming PDUFA May See Some Upside
STAMFORD, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alle
Cara (CARA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
The biotech stock is being added to an important small-cap index.
The shares of Cara Therapeutics Inc (NASDAQ:CARA) are up 13.1% to trade at $23.82  at last check -- their highest level in over a year -- on reports that the equity will be added to the S&P 600 Smal
Investors getting ready for another busy day of trading need to make sure they know the biggest pre-market stock movers before markets open. The post Today's Biggest Pre-Market Stock Movers: 10 Top Ga
The stock price of Cara Therapeutics Inc. (NASDAQ: CARA) increased by over 10% pre-market. This is why it happened.
STAMFORD, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alle
ST.GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the Europ
The FDA accepts Cara Therapeutics (CARA) and Vifor Pharma's NDA for Korsuva injection under a priority review to treat moderate-to-severe pruritus in hemodialysis patients. Shares rise.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE